Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention

European Heart Journal

Volumn 24, Issue 20, 2003, Pages 1824-1832

  Liu, Ping Yen ^a   Li, Yi Heng ^a   Tsai, Wei Chuan ^a   Chao, Ting Hsing ^a   Tsai, Liang Miin ^a   Wu, Hua Lin ^a   Chen, Jyh Hong ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acute coronary syndrome; Inflammation; Percutaneous coronary Intervention; Prognosis

Indexed keywords

C REACTIVE PROTEIN; CREATINE KINASE; CREATINE KINASE MB; PHOSPHOLIPASE A2; SECRETORY TYPE II PHOSPHOLIPASE A2; TROPONIN T; UNCLASSIFIED DRUG;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SMOKING; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERIOSCLEROSIS; CREATINE KINASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHOSPHOLIPASES A; PLASMA; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0142136633     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2003.07.003     Document Type: Article

References (36)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-26.
2. Rider PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
3. Kuller LH, Tracy RP, Shaten J et al. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144:537-47.
4. Koenig W, Sund M, Frohlich M et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
5. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-72.
6. Dennis EA. Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 1994;269:13057-60.
7. Pruzanski W, Vadas P. Phospholipase A2: a mediator between proximal and distal effectors of inflammation. Immunol Today 1991; 12:143-6.
8. Murakami M, Kudo I, Inoue K. Secretory phospholipase A2. J Lipid Mediat Cell Sign 1995;12:119-30.
9. Leitinger N, Watson AD, Hama SY et al. Role of group II secretory phospholipase A2 in atherosclerosis. Arterioscler Thromb Vasc Biol 1999;19:1291-8.
10. Sartupy P, Camejo G, Svensson L et al. Phospholipase A2 modification of low-density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem 1999;274:25913-20.
11. Packard CJ, O'Reilly DSJ, Caslake MJ, for the West of Scotland Coronary Prevention Group et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 2000;343:1148-55.
12. Kugiyama K, Ota Y, Takazoe K et al. Circulation levels of secretory Type II phospholipase A2 predict coronary events in patients with coronary artery disease. Circulation 1999;100:280-4.
13. Kugiyama K, Ota Y, Sugiyama S et al. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol 2000;86:718-22.
14. Menschikoeski M, Kasper M, Lattke P et al. Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis 1995; 118:173-81.
15. Hurt-Camejo E, Andersen S, Standal R et al. Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries: activity of the isolated enzyme on low-density lipoproteins. Arterioscler Thromb Vasc Biol 1997;17:300-9.
16. Elinder LS, Dumitrescu A, Larsson P et al. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol 1997;17:2257-63.
17. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
18. Berliner J, Leitinger N, Waston A et al. Oxidized lipids in atherogenesis: formation, destruction and action. Thromb Haemost 1997; 78:195-9.
19. Fuentes L, Hernandez M, Fernandez-Aviles FJ et al. Cooperation between secretory phospholipase A2 and TNF-receptor superfamily signaling: implications for the inflammatory response in atherogenesis. Circ Res 2002;91:681-8.
20. Hernandez M, Fuentes L, Fernandez-Aviles FJ et al. Secretory phospholipase A2 elicits proinflammatory changes and upregulates the surface expression of fas ligand in monocytic cells: potential relevance for atherogenesis. Circ Res 2002;90:38-45.
21. Matsuda Y, Ogawa M, Sakamoto K et al. Development of a radio-immunoassay for human group-II phospholipase A2 and demonstration of postoperative elevation. Enzyme 1991;45:200-8.
22. Nakano T, Ohara O, Teraoka H et al. Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells. FEBS Lett 1990;261:171-4.
23. Murakami M, Kudo I, Inoue K. Molecular nature of phospholipase A2 involved in prostaglandin 12 synthesis in human umbilical vein endothelial cells. J Biol Chem 1993;261:171-4.
24. Ross R. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
25. Hajjar DP, Pomerantz KB. Signal transduction in atherosclerosis: integration of cytokines and the eicosanoid network. FASEB J 1992; 6:2933-41.
26. Kume N, Gimbrone MA Jr. Lysophosphatidylcholine trascriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 1994;93:907-11.
27. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.
28. Vogel WC, Zieve L. Post-heparin phospholipase. J Lipid Res 1964; 5:177-83.
29. Nakamura H, Kim DK, Philbin DM et al. Heparin-enhanced plasma phospholipase A2 activity and prostacyclin synthesis in patients undergoing cardiac surgery. J Clin Invest 1995;95:1062-70.
30. Dua R, Cho W. Inhibition of human secretory class II phospholipase A2 by heparin. Eur J Biochem 1994;221:481-90.
31. Schwartz GG, Anders G et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-8.
32. Patrick W, Serruys JC, de Feyter P, Macaya C et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287:3215-22.
33. Wiebauer F, Kaun C, Zorn G et al. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Brit J Pharmacol 2002; 135:284-92.
34. Liu PY, Chen JH, Li YH et al. Synergistic effect of stromelysin-1 (matrix metallo-proteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost 2003;90:132-9.
35. Vita JA, Gokce N, Duffy SJ et al. Effect of atorvastatin on endothelium-dependent vasodilation in patients with coronary artery disease. Am J Cardiol 2003;91:857-60.
36. Kuo BS, Dryjski M, Bjornsson TD. Influence of nicotine and cotinine on the expression of plasminogen activator activity in bovine aortic endothelial cells. Thromb Haemost 1989;61:70-6.